Welcome to LookChem.com Sign In|Join Free

CAS

  • or

236750-65-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 236750-65-5 Structure
  • Basic information

    1. Product Name: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile
    2. Synonyms: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile;Erlotinib interMediate;2-nitro-4,5-bis(2-Methoxyethoxy)benzonitrile;4,5-Di(2-methoxyethoxy)-2-nitrobenzonitrile;Erlotinib Impurity 19;Erlotinib Impurity 32;Erlotinib Impurity W;Erlotinib intermediates
    3. CAS NO:236750-65-5
    4. Molecular Formula: C13H16N2O6
    5. Molecular Weight: 296
    6. EINECS: 1308068-626-2
    7. Product Categories: N/A
    8. Mol File: 236750-65-5.mol
    9. Article Data: 10
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 459.3oC at 760 mmHg
    3. Flash Point: 231.6oC
    4. Appearance: /
    5. Density: 1.26g/cm3
    6. Vapor Pressure: 1.28E-08mmHg at 25°C
    7. Refractive Index: 1.527
    8. Storage Temp.: 2-8°C
    9. Solubility: N/A
    10. CAS DataBase Reference: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile(CAS DataBase Reference)
    11. NIST Chemistry Reference: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile(236750-65-5)
    12. EPA Substance Registry System: 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile(236750-65-5)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 236750-65-5(Hazardous Substances Data)

236750-65-5 Usage

Description

4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile is an organic compound that is identified as an impurity in Erlotinib (E625008), a targeted drug used in the treatment of non-small cell lung cancer. It is characterized by its molecular structure that includes a nitro group and a cyano group attached to a benzene ring, with two methoxyethoxy substituents at the 4,5-positions.

Uses

Used in Pharmaceutical Industry:
4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile is used as an impurity in the production of Erlotinib, an EGFR small tyrosine kinase inhibitor. It is significant in the pharmaceutical industry due to its association with a drug that has a substantial effect on tumor growth inhibition and animal survival in the context of non-small cell lung cancer treatment.
The compound's presence as an impurity in Erlotinib highlights the importance of quality control and purification processes in the pharmaceutical manufacturing sector. Ensuring the purity and safety of drugs is crucial for their efficacy and the well-being of patients undergoing treatment.

Check Digit Verification of cas no

The CAS Registry Mumber 236750-65-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,3,6,7,5 and 0 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 236750-65:
(8*2)+(7*3)+(6*6)+(5*7)+(4*5)+(3*0)+(2*6)+(1*5)=145
145 % 10 = 5
So 236750-65-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H16N2O6/c1-18-3-5-20-12-7-10(9-14)11(15(16)17)8-13(12)21-6-4-19-2/h7-8H,3-6H2,1-2H3

236750-65-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 4,5-Bis(2-methoxyethoxy)-2-nitrobenzonitrile

1.2 Other means of identification

Product number -
Other names BENZONITRILE,4,5-BIS(2-METHOXYETHOXY)-2-NITRO

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:236750-65-5 SDS

236750-65-5Relevant articles and documents

Preparation method of erlotinib hydrochloride intermediate

-

, (2019/05/08)

The invention provides a preparation method of an erlotinib hydrochloride intermediate. The preparation method comprises following steps: removing the methyl of vanillin, performing esterification, converting an aldehyde group into a nitrile group, and carrying out nitration, reduction, hydrolysis, and ring forming reactions. The reaction route is represented in the description. The technology isreasonable, the operation is simple, the cost is low, and the reaction yield is high.

Synthesis method of erlotinib hydrochloride

-

, (2017/08/31)

The invention discloses a synthesis method of erlotinib hydrochloride. The synthesis method comprises the following steps: (1) at a first working section: preparing 3-methoxyl-4-hydroxybenzonitrile from vanillin and hydroxylammonium chloride; (2) at a second working section: synthesizing 3,4-dihydroxybenzonitrile; (3) at a third working section: synthesizing 3,4-di(2-methoxyethoxy)phenylacetonitrile; (4) at a fourth section: synthesizing 4,5-di(2-methoxyethoxy)-2-nitrophenylacetonitrile; (5) at a fifth working section: synthesizing 4,5-di(2-methoxyethoxy)-2-aminophenylacetonitrile hydrochloride; and (6) at a sixth working section: synthesizing the erlotinib hydrochloride. The synthesis method of the erlotinib hydrochloride, disclosed by the invention, has the advantages of reasonable design, easiness of obtaining raw materials, relatively low production cost, simplicity and easiness of operation and is suitable for industrial production.

Compounds for use in inhibiting HIV capsid assembly

-

, (2014/09/03)

The present invention relates to a compound or a pharmaceutically acceptable salt or solvate thereof for use in inhibiting HIV capsid assembly, the compound comprising the core structure wherein E is CR7or S, and wherein f is 0 or 1, and wherein in case E is S, f is 0, and wherein the core structure is at least substituted in 2 and 4 position, and wherein the residue R6 and R7, are, independently of each other, selected from the group consisting of -H, -D, -alkyl, alkoxy, alkenyl, alkynyl, halides, -NO2, - OH, - NH2, -NHR4#, -CN, -S(O)R4#, -SO2R4#, -P(O)R4#R5#, -P(O)(OR4#)R5#, - P(O)(OR4#)(OR5#), -C(O)NR4#R5#, -C(O)SR4#, -C(O)R4#, -C(O)O-R4#, alkoxy and glycol chains; and wherein R6 may optionally form a cyclic residue, with a further substituent present 5 or 6 position, and wherein R4# and R5# are, independently of each other, selected from the group consisting of -H, -alkyl, -alkenyl, - heterocycloalkyl, aryl and heteroaryl.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 236750-65-5